Asset Details
Do you wish to reserve the book?
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Do you wish to request the book?
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
2019
Overview
Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non–small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic.
Publisher
Elsevier Inc,Frontline Medical Communications Inc
Subject
/ Carcinoma, Non-Small-Cell Lung - diagnosis
/ Carcinoma, Non-Small-Cell Lung - epidemiology
/ Carcinoma, Non-Small-Cell Lung - prevention & control
/ Carcinoma, Non-Small-Cell Lung - therapy
/ Early Detection of Cancer - methods
/ Education, Medical, Continuing
/ Female
/ Humans
/ Lung Neoplasms - epidemiology
/ Lung Neoplasms - prevention & control
/ Male
/ Molecular Targeted Therapy - methods
/ Phenols (Class of compounds)
/ Tyrosine
